Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected~* Age ≥ 18 years~* Abtiretroviral-naïve, including above 7 days of cumulative prior antiretroviral therapy at any time prior to study entry.~* For women of childbearing potential: acceptance to use effective contraceptive methods~* Provision of written informed consent~Exclusion Criteria:~* Infection with HIV-1 group O, N, P~* Infection or co-infection with HIV-2~* Absolute neutrophil count (ANC) \< 500 cells/mm3~* Hemoglobin \< 7.0 g/dL~* Platelet count \< 50,000 cells/mm3~* AST and/or ALT \> 5 x Upper Limit of Normal (ULN)~* Calculated creatinine clearance \< 50 mL/min~* Active opportunistic or severe disease not under adequate control~* For women of childbearing age : Pregnancy/breastfeeding~* History or presence of allergy and/or contraindications to the trial drugs or their components~* Severe psychiatric illness~* Severe hepatic failure Patients co-infected with tuberculosis (TB), receiving a TB treatment and with stable clinical condition will not be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dolutegravir (Type: EXPERIMENTAL): Dolutegravir 50 mg Quaque die (QD) + tenofovir disoproxil fumarate/lamivudine 300 mg/ 300 mg Fixed Dose Combination (FDC) QD
- Efavirenz (Type: ACTIVE_COMPARATOR): Efavirenz 400 mg QD + tenofovir disoproxil fumarate/lamivudine 300 mg/ 300 mg FDC QD

Based on this trial design, predict the completion outcome and termination type (if applicable).